Summit Therapeutics Says Accepted Offers From Multiple Investors To Purchase Aggregate Of 10.35M Shares At $22.70 Per Share For Aggregate Gross Proceeds Of $235M
Summit Therapeutics Says Accepted Offers From Multiple Investors To Purchase Aggregate Of 10.35M Shares At $22.70 Per Share For Aggregate Gross Proceeds Of $235M
summit therapeutics表示已接受多家投資者購買總計1035萬股股票，每股價格爲22.70美元，總交易金額爲2.35億美元。
All of Summit's Section 16 officers participated in the capital raise. A total of $79 million was raised by insiders, including Robert W. Duggan, Dr. Maky Zanganeh, Manmeet S. Soni, and Bhaskar Anand, as well as Jeff Huber, a member of the Board of Directors, who invested via a controlled entity. The remaining $156 million was raised with multiple leading biopharma institutional investors.
所有Summit的第16條款的高級管理人員參與了資本籌集活動。內部人士籌集了總共$79,000,000，包括Robert W. Duggan、Dr. Maky Zanganeh、Manmeet S. Soni和Bhaskar Anand，以及董事會成員Jeff Huber通過受控實體進行投資。其餘的$156,000,000由多家主要生物製藥機構投資者籌集。
資訊熱榜
更新時間